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Abstract
COVID-19 vaccines based on the Spike protein of SARS-CoV-2 have been developed that
appear to be largely successful in stopping infection. However, therapeutics that can help
manage the disease are still required until immunity has been achieved globally. The identifi-
cation of repurposed drugs that stop SARS-CoV-2 replication could have enormous utility in
stemming the disease. Here, using a nano-luciferase tagged version of the virus (SARS-
CoV-2-ΔOrf7a-NLuc) to quantitate viral load, we evaluated a range of human cell types for
their ability to be infected and support replication of the virus, and performed a screen of
1971 FDA-approved drugs. Hepatocytes, kidney glomerulus, and proximal tubule cells were
particularly effective in supporting SARS-CoV-2 replication, which is in-line with reported
proteinuria and liver damage in patients with COVID-19. Using the nano-luciferase as a
measure of virus replication we identified 35 drugs that reduced replication in Vero cells and
human hepatocytes when treated prior to SARS-CoV-2 infection and found amodiaquine,
atovaquone, bedaquiline, ebastine, LY2835219, manidipine, panobinostat, and vitamin D3
to be effective in slowing SARS-CoV-2 replication in human cells when used to treat infected
cells. In conclusion, our study has identified strong candidates for drug repurposing, which
could prove powerful additions to the treatment of COVID.
Author summary
The identification of repurposed drugs that stop SARS-CoV-2 replication could have
enormous utility in stemming COVID-19. Here, using a nano-luciferase tagged version of
the virus (SARS-CoV-2-ΔOrf7a-NLuc) to quantitate viral load, we evaluated a range of
human cell types for their ability to be infected and support replication of the virus, and
performed a screen of 1971 FDA-approved drugs. Hepatocytes, kidney glomerulus, and
proximal tubule cells were particularly effective in supporting SARS-CoV-2 replication,
which is in-line with reported proteinuria and liver damage in patients with COVID-19.
Using the nano-luciferase as a measure of virus replication we identified 35 drugs that
reduced replication in Vero cells and human hepatocytes when treated prior to SARS-
CoV-2 infection and found amodiaquine, atovaquone, bedaquiline, ebastine, LY2835219,
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manidipine, panobinostat, and vitamin D3 to be effective in slowing SARS-CoV-2 replica-
tion in human cells when used to treat infected cells. In conclusion, our study has identi-
fied strong candidates for drug repurposing, which could prove powerful additions to the
treatment of COVID.
Introduction
The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) virus is having a widespread impact on global health with substantial loss of
life. SARS-CoV-2 infection in patients with COVID-19 can result in pulmonary distress,
inflammation, and tropism to multiple organs [1]. Some infected individuals are asymptom-
atic whilst others mount an exaggerated immune response, or ‘cytokine storm’[2,3], which
correlates with multiple organ failure and poor outcome [4]. Vaccines have been developed to
help protect people from COVID-19 but the emergence of mutational variants, some with
increased transmissibility, calls for additional research into alternative treatment and preven-
tion strategies.
An early step in the infection process is interaction of the Spike protein on the surface of
the virus with angiotensin-converting enzyme 2 (ACE2) on the surface of the host cell [5].
Using this information, first-generation vaccines have been generated against the Spike pro-
tein. SARS-CoV-2 entry can be potentiated by additional host factors including neuropilin-1
[6]. Once inside, the virus uses components of the host cell to replicate and secrete viral parti-
cles [7] and disrupt RNA handling and protein translation to suppress host defenses [8]. The
different stages of the disease, from the initial infection of host cells through to virus replica-
tion and the response (normal or extreme) of the immune system, offer opportunities to iden-
tify drugs, treatments, and therapies to help stop disease progression. Furthermore, large
proportions of the world’s population remain at risk of contracting COVID-19 as they wait to
be vaccinated, which has prompted governments to encourage people to continue to self-iso-
late, remain at home, and maintain social distancing. The identification of safe and easily dis-
tributed medications that can target the different stages of virus infection and replication,
could reduce the spread of SARS-CoV-2 and reduce the cases of COVID-19.
The Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
work with pharmaceutical companies to develop safe and effective drugs for the benefit of pub-
lic health. Using a library of 1971 FDA-approved compounds, here we used a traceable clone
of SARS-Cov-2 to identify well-characterized drugs that could potentially slow the infection
and replication of the SARS-CoV-2 virus in human cells.
We had previously developed an approach to quantitate collagen synthesis by using
CRISPR-Cas9 to insert the gene encoding NanoLuciferase (NLuc) into the Col1a2 gene in
fibroblasts [9]. Here, we adapted the approach to tag the SARS-CoV-2 virus with NLuc, and
then used the recombinant NLuc-tagged virus to monitor virus replication and to identify
drugs that slow the replication process. SARS-CoV-2 was originally recovered by culturing
human specimens in the African green monkey kidney cell line, Vero [10], and the virus read-
ily replicates in this cell type. We have performed initial screening in the Vero cell line, and to
draw reliable conclusions from our studies we performed a replicate screen in a human hepa-
tocyte cell line, HUH7. We evaluated a panel of human cell types for their ability to be infected
by SARS-CoV-2 and to support virus replication, and optimized culture conditions for each
cell type to provide a robust system for screening in human cells. We found that hepatocytes
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and kidney epithelial cells were proficient in supporting SARS-CoV-2 replication whereas
fibroblasts and lung epithelial cells supported only minimal replication.
Therapeutic compound screens have been performed using Vero cells infected with SARS-
CoV-2 [11–13], cell viability or presence of viral proteins have been used to evaluate effective-
ness of each therapeutic. Similar screens have also been performed in human cell types [12,14],
however many of the identified compounds are found to suppress virus infection [11]. Using a
nano-luciferase activity as a marker of virus replication we have evaluated how 1971 FDA-
approved compounds impact on SARS-CoV-2 replication, in Vero and HUH7 cells. Through
applying stringent criteria in our hit selection and confirming efficacy of these compounds in
suppressing replication in cells already infected with SARS-CoV-2, we identified a shortlist of
nine drugs that were effective in inhibiting SARS-CoV-2 replication. The drugs identified
included anti-cancer and anti-viral drugs, but also fewer toxic drugs such as atovoquone, ebas-
tine and vitamin D3. The multiple steps involved in virus infection and proliferation, means
that each of these drugs may have different molecular targets, and for some, additional targets
are still being elucidated. As these drugs are FDA-approved and with safe dosimetry already
established for use in patients, clinical trials could be initiated for these drugs within a rela-
tively short time frame.
Results
Generation of a traceable SARS-CoV-2 virus
High throughput screens have been developed to identify drugs suitable for re-purposing for
treatment of COVID19 (e.g., [11,15]). These screens have been performed in non-human cell
lines, such as Vero, and rely on secondary factors such as cell viability to identify candidates,
or markers that indicate virus infection. To monitor the replication of SARS-CoV-2 we have
generated a modified traceable virus where Orf7a is replaced with the sequence encoding
NanoLuciferase (SARS-Cov-2-ΔOrf7a-NLuc, Fig 1A). NanoLuciferase (NLuc) is an enzyme
that produces light when supplied with its substrate (coelenterazine) and is readily detectable
even at low quantities [9]. Orf7a has previously been removed in SARS-CoV and SARS-CoV-2
and yielded infectious and replicative virus particles, in order to accommodate the NLuc
sequence we followed these designs [16–18]. We have used a reverse-genetics approach to gen-
erate virus particles (S1 Fig), and plaque forming assays demonstrated that the replication of
SARS-CoV-2-ΔOrf7a-NLuc viruses were equivalent to the wild-type SARS-CoV-2 (Wuhan-
Hu-1, NC_045512.2) (Fig 1B). Viral RNAs (S1 Fig), and electron microscopy (Figs 1C, 1D
and S2) confirmed virus production. NLuc activity was readily detected in infected cultures
upon addition of the substrate coelentrazine (Fig 1E).
NLuc activity as a marker of virus replication
To monitor replication of the SARS-CoV-2-ΔOrf7a-NLuc virus, Vero cells were exposed to
increasing numbers of replicative virus particles (plaque forming units, PFU) and lumines-
cence was used as a measure of virus replication. Luminescence measurements were compared
to SARS-CoV-2-ΔOrf7a-NLuc virus in the absence of cells as background (Fig 2A), 24, 48 and
72 hours post infection (h.p.i.). A lag in virus replication of at least 48 hrs was observed but
replication was readily observed at 72 hrs, when as little as 2 PFU per well (MOI 0.0004) was
added. Using these optimization experiments 72 h.p.i. was chosen as the time point at which
to assess virus replication in subsequent assays, the average Z’ factor [19] for our replication
assay in 96 well format was 0.8 indicating suitability for library screening. Amplification of
NLuc signal upon virus infection was consistent for all passages of the traceable virus (S3 Fig)
and with varying cell number (S4 Fig).
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SARS-CoV-2 replication screen validation
High throughput screens have been developed to identify drugs suitable for re-purposing for
treatment of COVID19 (e.g., [11,13,20]). These screens have been performed in non-human
cell lines, such as Vero, and rely on secondary factors such as cell viability to identify candi-
dates. Other screening methods have used detection of viral proteins and have been able to
identify candidates that impact virus infection [12,14]. A first step in validating our viral repli-
cation screen was to measure virus replication after treatment with interferon alpha 2 (IFNA2)
which has previously demonstrated to reduce virus replication [17]. When Vero cells were
infected with a single PFU, pre-treatment of IFNA2 was able to reduce replication of SARS-
CoV-2-ΔOrf7a-NLuc in a dose dependent manner. However, with higher virus load (100
PFU), IFNA2 had little effect on virus replication (Fig 2C and 2D). These results provided
confidence that the NLuc-tagged virus system could be used to quantify the effects of drugs on
virus replication, especially if reduction of bioluminescence was detected with high PFU.
Drug repurposing to target SARS-CoV-2 replication
A 1971 FDA-approved compound library was used to pre-treat Vero cells before infection
with either 1PFU (MOI 0.0002) or 100 PFU (MOI 0.02) SARS-CoV-2-ΔOrf7a-NLuc virus as
Fig 1. Nanoluciferase (NLuc) modified SARS-CoV-2 virus as a reporter for virus replication. A) Diagram of the SARS-CoV-
2 genome highlighting the insert site for the reporter NLuc in place of Orf7a, (SARS-CoV-2-ΔOrf7a-NLuc). B) Virus particles
recovered following transfection of wild-type (WT) or NLuc modified SARS-CoV-2 encoding RNA into 293T cells were used to
infect Vero cells. The recovered virus (P1 virus) was then titered in Vero cells to assess virus replication and plaque forming
potential. C) Electron microscopy of the SARS-Cov-2 virus 72 h.p.i. of Vero cells (Passage 4, P4), both intra- and extra-cellular
virus particles were identified. D) Measurement of diameter for the wild-type (WT) and NLuc modified SARS-CoV-2 particles.
E) Measurement of NLuc activity in medium of Vero cells infected wild-type (WT) and NLuc modified SARS-CoV-2 virus
without and with addition of the NLuc substrate coelentrazine.
https://doi.org/10.1371/journal.ppat.1009840.g001
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outlined in Fig 3A. Infected Vero cells that were untreated and background (virus only wells)
were used as controls. The Z’ factor was assessed for each plate of the screen averaging 0.867±
0.140 SD and 0.915± 0.058 SD, for the 1PFU and 100PFU screen, respectively demonstrating a
robust assay. More hits were identified in the 1PFU screen and therefore we focused our hit
selection on compounds that reduced virus replication by at least 85% in the 100PFU screen
(Fig 3B and S1 Table). We identified 69 compounds that reduced replication (FDR<0.1 com-
pared to untreated and DMSO controls, 55 showed no viral replication). These hits were also
identified in the duplicate screen performed with 1PFU per well (Fig 3C). Five of these com-
pounds were false positive hits due to direct inhibition of NLuc activity (Fig 3C and S2 Table).
Drug repurposing screen for SARS-CoV-2 replication in human cells
Having established an effective screening strategy in Vero cells, we sought to establish a similar
approach in a human cell line capable of supporting SARS-CoV-2 replication. SARS-CoV-2
has been reported to infect multiple cell lines, and replication of the viral genome has been
identified [21]. We tested the replicative capacity of SARS-CoV-2-ΔOrf7a in the lung epithelial
Fig 2. Timings of SARS-CoV-2-ΔOrf7a-NLuc virus replication. A) Schematic showing how SARS-CoV-2 ΔOrf7a-
NLuc was used to assess virus replication. During virus replication as virus particles are released from the cell, or
because of cell death, NLuc activity is detected in the conditioned medium together with virus particles. In subsequent
assays the NLuc activity is recorded in the absence of cells, and NLuc signals above background signal are used to
indicate the level of virus replication. B) The replication of SARS-CoV-2-ΔOrf7a-Nluc was monitored in a 96 well
assay. Using 5000 Vero cells per well, increasing numbers of virus particles were added and monitored 24, 48 and 72
hrs post infection (h.p.i). Substantial and significant increases in NLuc activity were observed when only two plaque
forming units (PFU) were added. Higher NLuc activity was associated with higher viral input. Even with higher viral
inputs the substantial increases in NLuc activity occurred only after 72 h.p.i. C) Five thousand Vero cells were pre-
treated with increasing doses of IFNα2 for 24 hrs prior to infection with 1PFU SARS-CoV-2-ΔOrf7a-NLuc. NLuc
activity and viability were assessed 72 h.p.i. demonstrating effective inhibition of virus replication. The blue line
indicates the luminescence counts per second for DMSO treated controls. N = 3 replicate samples. D) As in C, 5000
Vero cells were treated with increasing doses of IFNα2 for 24 hours prior to infection with 100 PFU SARS-CoV-2-
ΔOrf7a-NLuc. With this higher titer, virus replication was not inhibited. The blue line indicates the luminescence
counts per second for DMSO treated controls. N = 3 replicate samples.
https://doi.org/10.1371/journal.ppat.1009840.g002
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cell lines Calu3, A549, and 16HBEo and in lung fibroblasts. Using real-time PCR and western
blotting for the SARS-CoV-2 nucleocapsid protein, we observed virus replication in these cell
lines, and we confirmed that SARS-CoV-2 WT and SARS-CoV-2-ΔOrf7a-NLuc viruses
infected these lung cell lines (S5 Fig). However, the Z’ factor suggested that they were not suit-
able for high throughput screening (Fig 4A), this was also observed for primary lung epithelial
cells (S6 Fig). We assessed additional cell lines reported to be infected by SARS-CoV-2 includ-
ing Caco-2 [20,21] and HUH7 [10], as well as additional kidney cell lines. These were chosen
as we were able to recover virus particles from 293T cells and kidney is reported to express
high levels of ACE2 [22]. Replication in monocytic cells and fibroblastic cell lines was also
monitored due to the systemic and fibrotic nature of COVID-19. We identified virus replica-
tion in HUH7 cells, microvascular cells of the kidney glomerulus, and proximal tubule cells of
the kidney and THP1 monocytic cells (Fig 4A).
As each cell line has a specific culture medium for optimal growth, we set out to test if dif-
ferent media would support cell growth and virus replication in lung epithelial cells, as this is
the primary site of Sars-CoV-2 infection. We used 15 different medium conditions to grow
lung epithelial cells prior to infection with SARS-CoV-2-ΔOrf7a-NLuc; for comparison,
HUH7 cells were also included. Changes in growth conditions improved assay performance in
lung epithelial and fibroblasts but signal-to-noise ratios remained low. In contrast, for HUH7
cells, these optimized conditions significantly improved the 96 well format assay as indicated
by Z’ factor>0.5 and signal-to-noise ratios>20 (Fig 4B and 4C). Using the 1971 FDA-com-
pound library we identified 223 compounds that suppressed SARS-CoV-2 replication by
greater than 85% whilst maintaining cell viability. We refined these hits by overlapping with
positive hits from the screen in Vero cells (Fig 4E and S3 Table). We identified 35 inhibitory
compounds and 2 compounds that increased NLuc activity, that were common to the two
screens (Fig 4F). The intended clinical use or targets of the 35 inhibitory compounds included
anti-virals, antibiotics, modifiers of dopamine and estrogen receptor activity, calcium ion
channel inhibitors and HMG-CoA reductase inhibitors (Fig 5A). The hits also identified
Fig 3. Screen of 1971 FDA-approved compounds to identify therapeutics that inhibit SARS-CoV-2-ΔOrf7a-NLuc virus
replication. A) Schematic of the screening procedure used to assess whether FDA-approved compounds alter SARS-CoV-2
ΔOrf7a-NLuc virus replication. B) Scatterplot showing the effects of 1971 compounds on SARS-CoV-2 ΔOrf7a-NLuc replication
and cell viability. C) Scatterplot showing the effects of 1971 compounds on SARS-CoV-2 ΔOrf7a-NLuc replication in replicate
screens using 100 PFU or 1 PFU per well. The Z-score for luciferase activity is plotted. D) Scatterplot of 50 compounds that
reduced NLuc activity in C. The luciferase activities relative to untreated controls (indicated by the blue dashed line) are shown.
Highlighted in green are compounds that inhibit the NLuc enzyme directly.
https://doi.org/10.1371/journal.ppat.1009840.g003
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vitamin D3, which is available over the counter. Multiple vitamin D related compounds were
present in the screen and these too suppressed SARS-CoV-2-ΔOrf7a-NLuc although these did
not all meet our criteria for both Vero and human cell lines (Fig 5B).
These initial hits were further tested to determine if treatment could also prevent replication
in cells already infected with SARS-CoV-2-ΔOrf7a-NLuc. We infected Vero cells with
Fig 4. Replication of SARS-CoV-2-ΔOrf7a-NLuc in human cell lines. A) SARS-CoV-2 replication in human cell lines. Five
thousand cells per well were seeded and infected as in Fig 3A. All cells were grown in the recommended growth medium, detailed
in Table 1. The NLuc activity after 3 days was used to assess the degree of virus replication. NLuc activity above the baseline activity
is shown as a heat map. Each box is the average of 2 biological repeats of each cell line at each virus dose, with the same findings
observed when 2000, or 10,000 cells were seeded. B) Lung epithelial, fibroblasts, HUH7 and 293T cell lines were grown in 15
different growth medium compositions. NLuc activity over background three days after infection is shown. Each row represents a
different growth medium as indicated in C). Each box represents 4 replicate measures of replication. Similar findings were
observed in n = 6 biological repeats. Z’ factors were calculated for each virus dose using ‘virus only’ wells as negative controls, the
average Z’ factor for each growth medium is shown. The signal-to-noise ratio of infected cells relative to ‘virus only’ wells are also
shown. C) NLuc activity above background three days after infection in HUH7 cells. Each box represents 4 replicate measures of
replication. Similar findings were observed in n = 6 biological repeats. D) The effects of 1971 FDA-approved compounds on the
replication of SARS-CoV-2-ΔOrf7a-NLuc (100 PFU/well, MOI 0.02) in HUH7 cells grown in alpha-MEM supplemented with 10%
FBS. Five thousand cells were treated with 10 μM of each compound for 24 hrs prior to infection with 100 PFU of virus. Virus
replication progressed for 72 hrs as in Fig 3A. E) Comparison of compounds identified by screening for HUH7 and Vero cells Z-
scores for luciferase activity are shown. Comparison and overlap of inhibitors identified in the compound screening for HUH7 and
Vero cells.
https://doi.org/10.1371/journal.ppat.1009840.g004
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SARS-CoV-2 for 24 hrs (which is sufficient time for the virus to begin replication) then added
each of the 35 inhibitor compounds. The cells were incubated for 48 hrs (i.e. a total of 72 h.p.i)
prior to bioluminescence being measured. Most of the compounds had no impact on virus
replication; but 9 of the 35 compounds reduced replication relative to DMSO controls
(Table 1, S7 Fig). The effective doses for these compounds were then determined in HUH7
cells to provide a future reference for selecting dose after comparison to pharmacokinetic data
established in human trials (Fig 5, Table 1). We also tested the ability of these 9 compounds to
inhibit the replication of the wild-type SARS-CoV-2 virus in HUH7 cells, all compounds
reduced virus titers (Fig 6). Whilst these are pre-clinical in vitro data, they demonstrate the
efficacy of the compounds in reducing virus replication post infection and warrant further
investigation to determine if these could ease the burden of the virus in patients.
Fig 5. Dose response of SARS-CoV-2 inhibitors. A) Summary of the inhibitor class of the 35 compounds identified in both the
Vero and HUH7 screens. B) Effects of vitamin D related compounds from the APExBIO DiscoveryProbe library on NLuc
activity in the Vero and HUH7 screens. C) Dose responses to the 9 compounds in HUH7 cells. Cells were treated and infected as
described in Fig 4D. NLuc activity relative to DMSO controls are shown in blue, and viability relative to DMSO are shown in
black. N = 2 independent repeats are shown.
https://doi.org/10.1371/journal.ppat.1009840.g005
PLOS PATHOGENS SARS-CoV-2 re-purposed drugs
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1009840 September 9, 2021 8 / 19
Discussion
In this study we have shown that the SARS-CoV-2 virus infects and replicates in a range of
human cells especially hepatocytes, kidney glomerulus, and proximal tubule cells of the kidney,
and, that 9 drugs that have previously been shown to be safe in humans and approved by the
Table 1. Approved uses of the 9 compounds of interest that inhibit SARS-CoV-2 infection and replication in HUH7 cells.
Compound HUH7
IC50
Vero IC50 Post-infection at
IC50
Approved Use Target
Panobinostat <0.2 μM <0.2 μM -25% Multiple myeloma HDAC inhibitor
LY2835219 0.2 μM 1 μM -40% Abemaciclib for advanced breast cancer CDK4/6 inhibitor
Manidipine 2 μM 7.5 μM -50% Anti-hypertensive Calcium channel blocker
Manidipine
2HCl
2.5 μM 7.5 μM -50% Anti-hypertensive Calcium channel blocker
Ebastine 0.5 μM 5 μM -25% Anti-histamine for allergic rhinitis and chronic
idiopathic urticaria
H1 receptor blocker
Atovaquone 7.5 μM 3 μM -25% antimicrobial (anti-malarial) Selective inhibitor of parasite mitochondrial
electron transport
Bedaquiline 5 μM 10 μM -30% pulmonary tuberculosis mycobacterial ATP synthase
Vitamin D3 3 μM 10 μM -30% Common supplement Transcriptional/calcium regulation
Amodiaquine 1 μM 5 μM -25% antimicrobial (anti-malarial) Inhibitor heme polymerase activity
https://doi.org/10.1371/journal.ppat.1009840.t001
Fig 6. Effect of inhibitors on wild-type SARS-CoV-2 replication. A) SARS-CoV-2 replication in HUH7 cells treated with
identified inhibitors was assessed by titering virus-containing medium. B) Example plaques obtained using medium from
control (untreated or DMSO treated) or treated cultures of HUH7 cells infected with wild-type 100 PFU SARS-CoV-2. Medium
was diluted 1000-fold to assess numbers of plaque forming units in treated samples. C) Wild-type virus titers from HUH7 cells
treated with varying doses of the 9 compound hits. N = 3 independent repeats are shown, error bars represent the standard
deviation.
https://doi.org/10.1371/journal.ppat.1009840.g006
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FDA for clinical use are effective in inhibiting SARS-CoV-2 replication even after infection.
We have demonstrated that, whilst we were able to slow virus replication with many more
compounds if cells were pretreated prior to infection, many of these compounds failed to
impact on virus replication if applied after infection. This finding is supported by observations
of a large compound library screen in Vero cells which demonstrated that many of the identi-
fied compounds suppressed virus uptake [11].
The identification that liver and kidney cells are infection and replication competent for
SARS-CoV-2 aligns with the observed liver and kidney abnormalities in patients with
COVID-19. Liver comorbidities have been reported in 2–11% of patients with COVID-19, and
14–53% of cases reported abnormal levels of liver enzymes [23], with liver injury being more
prevalent in severe cases (reviewed by [24]). Another study reported that patients with chronic
liver disease, especially African Americans, were at increased risk of COVID-19 [25]. It has
been suggested that liver damage in patients with COVID-19 might be caused by viral infec-
tion of liver cells, which is supported by the presence of SARS-CoV-2 RNA in stool [26]. On a
similar note, acute kidney injury is a common complication of COVID-19 and has been asso-
ciated with increased morbidity and mortality (reviewed by [27]). Our data showing SARS-
CoV-2 infection and replication in kidney cells helps to explain kidney pathology associated
with COVID-19.
RECOVERY [28] has set out to identify therapeutics that could be re-purposed for treat-
ment of COVID patients. For example, dexamethasone, which is a broad spectrum immuno-
suppressor, has been applied clinically to inhibit the destructive effects of the cytokine storm
and shown to reduce mortality and decrease the length of hospitalization [29], did not demon-
strate any effect on viral replication in our study. It may be possible in the future to combine
the therapeutics identified in our study with dexamethasone so that both the cytokine storm
and virus replication are targeted.
Of interest, other therapeutics that have been tested in the RECOVERY trial include rito-
navir and lopinavir (antiretroviral protease inhibitors), which failed to show clinical benefit
in the treatment of COVID-19 [30]. These drugs were present in the DiscoveryProbe library
used in our study but showed no significant effect on SARS-CoV-2 replication, in our
assays. Anti-viral agents such as Ritonavir and Lopinavir, which failed to show effects in the
RECOVERY/AGILE trials, also failed to halt replication of SARS-CoV-2 in either our Vero
or HUH7 cell screens. Other trialled compounds such as hydroxychloroquine and azithro-
mycin did show some effects in HUH7 cells but these effects were largely due to their toxic
effects on cells.
The high costs and lengthy lead-in times associated with new drug development, make
repurposing of existing drugs for the treatment of common and rare diseases an increasingly
attractive idea (for review see [31]). The approaches used include hypothesis driven, preclinical
trials including computational (e.g., computational molecular docking) and experimental (e.g.,
biochemical or cell-based assays of drug interactions) methods, and evaluation of efficacy in
phase II clinical trials. As noted by Pushpakom et al., of these three steps, the identification of
the right drug for an indication of interest (in our case SARS-CoV-2 and COVID-19) is
critical.
The nine drugs that we identified here have been approved for use in the treatment of a
variety of diseases. Panobinostat, for example, is a HDAC inhibitor that blocks DNA replica-
tion, and has been used to inhibit cell growth in the management of cancer. Panobinostat had
the strongest effect on limiting SARS-CoV-2 replication whilst maintaining cell viability, and
completely blocked replication of SARS-CoV-2 at all doses tested (Fig 5); however, if cells
were infected prior to treatment a more modest effect on replication were observed. This dif-
ference may be related to the recent observations that panobinostat can suppress ACE2
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expression [32], which would explain its beneficial effect prior to entry of the virus into cells
and not thereafter. Abemaciclib (LY2835219) is another cell cycle inhibitor, suppressor of
DNA replication and anti-cancer drug that emerged from the screen however these are likely
to be detrimental to recovery from SARS-CoV-2 infection.
Atovaquone is of particular interest because it has been identified in other studies of SARS-
CoV-2 in the context of COVID-19. It is a hydroxynaphthoquinone approved by NICE for the
treatment of mild to moderate pneumocystis pneumonia and as a prophylaxis against pneu-
mocystis pneumonia. It also has been used in combination with proguanil (Malarone) as an
antimalarial. The mechanism of action of atovaquone has been widely studied; it is a competi-
tive inhibitor of ubiquinol, and against P. falciparum, it acts by inhibiting the electron trans-
port chain at the level of the cytochrome bc1 complex [33]. A more recent study showed that
atovaquone inhibits Zika and Dengue virus infection by blocking envelop protein-mediated
membrane fusion [34]. Furthermore, in silico molecular docking strategies suggested potential
binding of atovaquone to the SARS-CoV-2 spike protein [35,36]. These two mechanisms of
action help to explain how atovaquone slows both infection and replication of SARS-CoV-2 in
cells.
Our observation that bedaquiline inhibits SARS-CoV-2 replication supports evidence from
an in silico repurposing study in which bedaquiline was proposed to be a promising inhibitor
of the main viral protease of SARS-CoV-2 [37]. The main protease cleaves pp1a and pp1ab
polypeptides, which encode nonstructural proteins to form the replication-transcription com-
plex [38], and help explain how inhibitors to the main protease are effective in inhibiting repli-
cation of SARS-CoV-2 in Vero 76 cells [39]. Manidipine (a calcium ion channel blocker
approved for the use in treating hypertension) is proposed to reduce the activity of the main
protease of SARS-CoV-2 [40] and limit the availability of calcium ions, which are required for
insertion of the coronavirus fusion peptide into the host lipid bilayers during viral fusion [41].
Our screen also identified ebastine (a second generation H1 receptor antagonist that has
been approved for the treatment of allergic rhinitis and chronic idiopathic urticaria) and vita-
min D3, which is a health supplement available over the counter. However, histamine antago-
nists exhibit effects in addition to blockage of the histamine receptor. For example, ebastine
blocks the release of anti-IgE-induced prostaglandin D2 [42]. The vitamin D receptor (VDR, a
member of the nuclear hormone receptor superfamily) is proposed to be essential for liver
lipid metabolism because its deficiency in mice protects against hepatosteatosis [43]. Once
bound to VDR, vitamin D plays a major role in hepatic pathophysiology, regulation of innate
and adaptive immune responses, and might contribute to anti-proliferative, anti-inflammatory
and anti-fibrotic outcomes (reviewed by [44]). Thus far, whether vitamin D supplementation
reduces the risk of SARS-CoV-2 infection or COVID-19 severity is unclear [45]. Whilst vita-
min D3 met the stringent cut-offs of 85% virus reduction, vitamin D2 and other vitamin D
related therapeutics also reduced virus replication but did not meet all criteria across both
Vero and HUH7 cell lines.
In conclusion, our study has identified compounds that are safe in humans and show effec-
tiveness in reducing SARS-CoV-2 infection and replication in human cells, especially hepato-
cytes. Their potency in stopping SARS-CoV-2 replicating in human cells in the face of the
COVID pandemic, warrants further study.
Materials and methods
Cell culture
Cell lines maintained in growth medium are shown in S4 Table.
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Generation of functional SARS-CoV-2 virus
DNA encoding the genome of SARS-CoV-2 and SARS-CoV-2-ΔOrf7a-NLuc were purchased
from Vectorbuilder Inc. (Chicago, US). Transfection of DNA encoding the viruses failed to
generate replicative virus when electroporated into 293T cells. We therefore produced RNA
molecules which encoded the virus in vitro. Briefly, virus encoding DNA (1 μg) was tran-
scribed using T7 mMessenger mMachine (Thermo) with a GTP:Cap ratio of 2:1 used in a
20 μL reaction. In addition, RNA encoding the SARS-CoV-2 nucleocapsid was also generated
by PCR using primers P1 and P2 (S5 Table). It has been reported that this aids the recovery of
replicative virus [18]. Viral RNA genomes (10 μl) and 2.5 μL nucleocapsid RNA were electro-
porated into 293T cells within the BSL3 laboratory. Viral RNAs were electroporated (5,000,000
cells, 1100 V, 20 ms and 2 pulses) and grown in T75 cm2 flasks and 24 well plates. Cells grown
in 24 well plates for 24–120 hrs were used to monitor changes in NLuc activity.
Virus production, maintenance and assessment of titer
Culture medium was collected from 293T cells 6 days after electroporation. This virus (P0)
was used to infect cells of interest. As virus replication was slow in 293T cells, virus stocks were
maintained by passage in Vero cells grown in DMEM supplemented with 2% FBS. Medium (1
mL) was used to infect Vero cells in order to generate P1 virus. Replication was assessed by
measuring NLuc activity over 10 days. For subsequent passage of the virus, Vero cells in T75
cm2 flasks were infected with 2 mL of medium containing virus, after 3 days the medium was
collected and passed through 0.45 μm filters using Luer-loc syringes.
To titer the virus, 200,000 Vero cells were seeded in 6-well plates overnight in growth
medium. After removing growth medium Vero cells were infected with 200 μL of serially
diluted virus containing medium at 37˚C. After 1 hour, wells were overlaid with 2 mL of 0.3%
low melt agarose in 2x DMEM containing 1% FBS and grown for 3 days. After 3 days infected
cells were fixed with 10% PFA overnight and then stained with crystal violet. Plaques were
identified by imaging plates on BioDoc-It gel documentation system (UVP, Upland, US).
To detect viral RNA in medium, 0.25 mL of virus containing medium was collected 3 days
post infection, 0.75 mL TriPure LS reagent (Sigma-Aldrich St. Louis, US) was added, and RNA
isolated according to the manufacturer’s recommendations, in the final step RNA was dis-
solved in 15 μL DNAse/RNAse free water. For detection of SARS-COV-2 nucleocapsid tran-
scripts in lung epithelial cells, 200,000 cells were infected at the indicated MOI for 3 days,
monolayers were lysed directly in 1 mL Trizol (Invitrogen, Paisley UK). For assessing expres-
sion of ACE2, TMPRSS2 and NLP1 expression in lung epithelial cells RNA was isolated from
the cells using Trizol and RNA isolated according to the manufacturer’s recommendations.
For cDNA generation and real-time PCR we used conditions previously described [46] using
primers detailed in S5 Table.
Electron microscopy
After 3 days infection with P4 virus, Vero cells were scrapped and pelleted. Cell pellets were
fixed using 2.5% glutaraldehyde and 4% paraformaldehyde in 0.1 M cacodylate buffer for 24 h,
washed in ddH2O three times, 30 mins for each wash. Cell pellets were incubated in freshly
made 2% (vol/vol) osmium tetroxide and 1.5% (wt/vol) potassium ferrocyanide in cacodylate
buffer (100 mM, pH 7.2) for 1 hr at room temperature. Samples were washed in ddH2O five
times each for 3 minutes. Specimens were transferred to freshly made 1% (wt/vol) tannic acid
in 100 mM cacodylate buffer (pH 7.2) for 40 mins at RT and washed in ddH2O five times for 3
mins each at RT. The specimen was incubated with 1% (vol/vol) osmium tetroxide in ddH2O
for 30 minutes at room temperature and washed in ddH2O three times for 5 min each at room
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temperature. The specimen was then incubated with 1% (wt/vol) uranyl acetate (aqueous) at
4˚C for 16 hrs (overnight) and then washed in ddH2O three times for 5 mins each time at
room temperature.
Specimens were dehydrated in graded ethanol: 30, 50, 70, 90% (vol/vol) ethanol in ddH2O
for 10 mins at each step. Then samples were washed four times for 10 mins each time in 100%
ethanol at room temperature. Samples were transferred to propylene oxide for 10 mins at
room temperature.
The specimen was finally infiltrated in a graded series of Agar100Hard in propylene oxide
at room temperature: first for 1 hour in 30% (vol/vol) Agar100Hard, 1 hr in 50% (vol/vol)
Agar100Hard then overnight in 75% (vol/vol) Agar100Hard, and then 100% (vol/vol)
Agar100Hard for 5 hrs. After transferring samples to freshly made 100% Agar100 Hard in
labelled molds and allowed to cure at 60˚C for 72 hrs. Sections were imaged on an FEI Tec-
nai12 BioTwin.
NLuc activity assay
Vero cells grown in 24-well plates (Corning, 3526) were assayed for NLuc activity by adding
1 μL of coelenterazine (final concentration 1.5 μM). For 96 well formats, cell lines were seeded
in white walled microwell plates (Nunc MicroWell 96-Well, Nunclon Delta-Treated, Flat-Bot-
tom Microplate, Thermo Fisher Scientific, Paisley, UK# 136101). To measure NLuc activity,
0.5 μL coelenterazine was added per well (final concentration 3 μM). Light production was
measured using filter cubes #114 and #3 on the Synergy Neo2 Multi-Mode Reader (Biotek),
readings for each well were integrated over 200 ms with 4 replicate measurements per well
(Gain 135 and read height 6 mm). For viability measurements, 2.5 μL Prestoblue (Thermo
Fisher Scientific, Paisley UK) was added per well incubated for 10 mins before reading fluores-
cence at Excitation: 555/20 nm, Emission: 596/20 nm (Xenon flash, Lamp energy low, Gain
100 and read height 4.5 mm, 10 measurements per data point).
Drug screens
The DiscoveryProbe FDA-approved library of 1971 compounds (L1021, APExBIO Boston,
US) was prepared as follows. After thawing the library for 4 hours at room temperature the
library was arrayed into 96 well plates at 1 mM in DMSO and stored at -20˚C. Stocks (1 mM)
were thawed at room temperature for 2 hrs before compounds were added to cells.
For all drug screens and validation, 5000 cells were seeded in 50 μL of growth medium for
24 hrs in white walled microwell plates. DMEM containing 2% FBS was used for Vero cells
and alpha-MEM containing 10% FBS was used for HUH7 cells. The following day 0.5 μL of
each compound (final concentration 10 μM) was added per well and incubated for 24 hours.
Eighty-eight compounds were tested per plate and each plate contained the following controls:
two untreated wells, two DMSO treated wells, and one well treated with 10 μM puromycin to
kill cells. SARS-CoV-2-ΔOrf7a-NLuc virus was added to all wells. In addition, two wells did
not contain any cells but were infected with the SARS-CoV-2-ΔOrf7a-NLuc virus as a measure
of background NLuc activity. A final well which contained cells but were uninfected were also
included. Twenty-four hours after drug treatment, cells were infected with 100 PFU per well
SARS-CoV-2-ΔOrf7a-NLuc virus in 50 μL of the indicated growth medium for 72 hrs. To
assess virus replication and viability, 2.5 μL of Prestoblue was added to each well and plates
incubated for 10 mins at 37˚C. Coelenterazine was then added to a final concentration of
3 μM. Plates were sealed prior to reading luciferase activity and viability as described above.
Validation of hits were performed using the same procedures described for the drug screen.
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Study design and statistical analysis
To identify hit compounds, raw luciferase luminescence reads (x) were normalized relative to





This meant that a normalized luciferase value of 1 implied no difference from untreated
virus replication, and a value of 0 represented total inhibition of viral replication.
The PrestoBlue reads (p) were normalised relative to the virus-infected DMSO-treated con-




This meant that a normalized PrestoBlue value of 1 implied no difference in cell viability
from DMSO-treated virus infected cells, and a value of 0 representing maximal reduction in
cell viability.
Z-scores were calculated relative to the mean log2(fold change) for each plate.
Compounds were categorized as either inhibitors or enhancers of NLuc-SARS-CoV-2
activity. Inhibitors were compounds where normalized NLuc-SARS-CoV-2 levels (xnorm) was
reduced such that xnorm<0.15, and cell viability as measured by normalised PrestoBlue levels
(pnorm) wasn’t affected by more than 50%, such that pnorm>0.5.
Where indicated one-tailed Student’s T-test were performed to evaluate significance in
changes to NLuc activity.
Supporting information
S1 Fig. Recovery of replication competent SARS-CoV-2 from synthetic DNA constructs.
A) Schematic for the recovery of SARS-CoV-2 virus particles from DNA encoding the wild
type and NLuc modified SARS-CoV-2 genome. RNA was transcribed from the synthetic DNA
constructs and electroporated into 293T cells, the cells were monitored daily for NLuc activity
and evidence of the cytopathic effects of virus replication. Virus containing medium was col-
lected 6 days post electroporation. B) NLuc activity in 293T cells electroporated with wild type
and NLuc modified SARS-CoV-2 RNA transcripts. C) Real-time PCR primer validation using
SARS-CoV-2 encoding DNA. NLuc coding sequences were inserted in place of the Orf7a
gene. Primers designed to amplify sequences within the DNA constructs confirmed primer
specificity. The number of cycles for each gene were normalized to those of the WT virus, or
for NLuc, to ΔOrf7a NLuc. For each DNA construct the qPCR data was also normalized to the
number of cycles obtained for the N gene (N = 3 technical repeats). D) Real-time qPCR detec-
tion of viral RNAs in the medium of infected Vero cells 72 h.p.i. Vero cells were infected with
SARS-CoV-2 WT (MOI 0.1) or SARS-CoV-2 ΔOrf7a-NLuc (MOI 1). E) Initial assessment of
viral replication in Vero cells. Twenty-four h.p.i. NLuc activity was readily detected in SARS-
CoV-2 ΔOrf7a-NLuc infected samples (N = 3 replicate samples). F) NLuc activity in Vero cells
infected with wild type SARS-CoV-2 or SARS-CoV-2 ΔOrf7a-NLuc modified virus. NLuc
activity was significantly elevated in SARS-CoV-2 ΔOrf7a-NLuc infected cultures across all
time points, ��� represents p<0.001 in a Students T-Test, N = 3 replicate samples. With pro-
longed culture NLuc activity within infected samples increased approximately 30-fold.
(TIF)
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S2 Fig. Detection of SARS-CoV-2 virus particles in Vero cells infected with passage 4 virus
stocks. A) After 4 passages of recovered wild type SARS-CoV-2 virus particles in Vero cells,
naïve Vero cells were infected and fixed 72 h.p.i. Viral particles could be observed inside and
outside of Vero cells indicated by red arrows. Scale bar, 2 μm. B) Higher magnification image
of an independent region of the sample in A. Scale bar, 0.5 μm. C) After 4 passages of recov-
ered SARS-CoV-2-ΔOrf7a-NLuc virus particles in Vero cells, naïve Vero cells were infected
and fixed 72 h.p.i. Viral particles could be observed inside and outside of Vero cells indicated
by blue arrows. Scale bar, 2 μm. Higher magnification image of an independent region of the
sample in C. Scale bar, 0.5 μm.
(TIF)
S3 Fig. Replication assays for different passages of SARS-CoV-2-ΔOrf7a-NLuc virus. A)
The plots show 5000 Vero cells infected with different volumes of virus harvested from repeat
passages of the virus (P) in Vero cells. With increasing viral load, there is an increase in back-
ground as more NLuc activity is added to each well (Blue). The background signal arises when
NLuc, expressed as the virus replicates, is released from infected cells that have lysed upon lib-
eration of the virus particles. N = 2 independent experiments. Similar data were obtained with
2,000 cells and 10,000 cells as shown in S4 Fig. B) After subtracting the background noise
observed in wells without cells (blue in A), the additional NLuc activity generated through
viral replication showed comparable signals for each virus passage. C) The signal-to-noise
ratio for each batch was used to identify the optimal conditions for virus replication for subse-
quent screening experiments. D) Comparison of luminescence signals for virus alone or after
incubation with 5000 Vero cells. Luminescence signals are shown relative to the number of
PFU for each virus stock. For all panels N = 2 independent experiments, error bars show the
standard deviation of repeat measurements of both experiments.
(TIF)
S4 Fig. SARS-CoV-2-ΔOrf7a-NLuc replication optimization. NLuc activity at different
times after infection with increasing numbers of SARS-CoV-2 virus particles. Enhanced NLuc
signals were observed 72 h.p.i. when either A) 2000, B) 5000 or C) 10,000 cells per well were
used. Maximal signals were generated with 5000 cells per well, as seeding 10,000 cells tended
to reduce NLuc activity. Five thousand cells were used for all subsequent assays.
(TIF)
S5 Fig. Detection of SARS-CoV-2 infection in lung epithelial cells. A) Real-time PCR detec-
tion of SARS-CoV-2 nucleocapsid (N) RNA in cells 72 h.p.i. Viral RNAs were readily detected
in cells infected with WT or ΔOrf7a-NLuc virus particles. N = 3 independent experiments. B)
Western blot detection of SARS-CoV-2 nucleocapsid (N) protein in cells 72 hours post infec-
tion. Lower levels of the N protein are detected in fibroblasts and lung epithelial cells when
compared to 293T and Vero cells suggesting the virus can infect but not replicate in these cell
lines. C) Real-time detection of known mediators of SARS-CoV-2 entry into cells. ACE2,
NLP1 and TMPRSS2 RNA levels are shown relative to RPLP0. Infectious virus in lung cell
lines but no replication.
(TIF)
S6 Fig. Replication of SARS-CoV-2-ΔOrf7a-NLuc virus in primary lung epithelial cells.
Luciferase counts per second in wells containing virus alone or virus with 5000 primary
human lung epithelial cells (CC-2547, Lonza) 72 h.p.i. A small (1.25-fold) increase in signal
was observed with 1000 PFU however this was not significant p>0.05, Student’s T-test and the
Z’ factor in these cells was less than 0.1.
(TIF)
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S7 Fig. Effective compounds that suppress SARS-CoV-2 replication with treatment com-
mencing after infection. A) Schematic for assessing whether any compounds that suppressed
virus replication prior to infection could also affect replication post-infection. B) Fifty com-
pounds identified to suppress SARS-CoV-2 replication in Fig 3 were assessed to identify dose-
dependent effects on SARS-CoV-2 replication with treatment progressing after infection (as
outlined in A). Nine compounds were found to suppress replication in a dose dependent man-
ner. N = 3 independent experiments, individual data points from each experiment are shown.
(TIF)
S1 Table. Source and growth conditions for cell lines used in this study.
(XLSX)
S2 Table. Primers used in this study.
(XLSX)
S3 Table. Inhibitors of Sars-CoV-2-ΔOrf7a-Nluc replication in Vero cells.
(XLSX)
S4 Table. Effects of identified Inhibitors of Sars-CoV-2-ΔOrf7a-Nluc replication on
recombinant NLuc activity.
(XLSX)
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